Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations
A pilot randomized controlled trial tested psilocybin-assisted psychotherapy in 30 adults with severe alcohol use disorder and depression who had recently completed detoxification. Participants received either 25 mg or 1 mg of psilocybin in two sessions three weeks apart, alongside standard care. At 12 weeks, the 25 mg group had a significantly higher abstinence rate (55% vs 11%), greater reductions in drinking days and craving frequency, and a lower relapse rate (35% vs 50%), though the latter difference was not statistically significant. Blinding was imperfect, and one serious adverse event (myocardial infarction) occurred in the 25 mg group, deemed unrelated. The treatment appears feasible, acceptable, and safe in this population.